Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 2Completed 2Terminated 1Approved for marketing 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4Observational 1Expanded_access 1

Sponsor

Cancer Type

Dermatologic 6Thoracic 2Head & Neck 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 38Melanoma 15Neoplasm Metastasis 12Squamous Cell Carcinoma of Head and Neck 11Lung Neoplasms 11Skin Neoplasms 10Neoplasms 9Ovarian Neoplasms 8Recurrence 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Urinary Bladder Neoplasms 6Head and Neck Neoplasms 6Carcinoma, Basal Cell 6Breast Neoplasms 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Colonic Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Merkel Cell 5Carcinoma 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Mouth Neoplasms 4Glioblastoma 4Fallopian Tube Neoplasms 4Stomach Neoplasms 3Sarcoma 3Mycosis Fungoides 3

Interventions

Nivolumab 7cemiplimab 6Specimen Handling 5HhAntag691 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Biopsy 4sonidegib 3pembrolizumab 3CTLA-4 Antigen 3relatlimab 2prednylidene 2deltacortene 2daromun 2Surgical Procedures, Operative 2Standard of Care 2Prednisone 2Observation 2Aminolevulinic Acid 2tocilizumab 1talimogene laherparepvec 1poly ICLC 1flt3 ligand protein 1X-Rays 1Watchful Waiting 1Vitamin D 1Tomography, Optical Coherence 1Therapeutics 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Carcinoma, Basal Cell × cemiplimab × 1 year × Clear all
NCT05929664 2026-03-24

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Thomas Jefferson University

Phase 2 Recruiting
70 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT06981325 2026-03-11

CEMI-first

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Recruiting
34 enrolled
Dermatologic

Carcinoma, Basal Cell, Skin Neoplasms

NCT03889912 2026-01-21

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Regeneron Pharmaceuticals

Phase 1 Completed
97 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT04916002 2025-12-05

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Regeneron Pharmaceuticals

Phase 2 Terminated
77 enrolled 18 charts
BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT06132191 2025-11-20

Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals

Approved for marketing
DermatologicThoracic

Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung

NCT03836105 2025-10-15

CASE

Regeneron Pharmaceuticals

Completed
287 enrolled
Dermatologic

Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡